Management of Congenital Adrenal Hyperplasia

Antony, Gabriel

doi:10.1016/s0140-6736(84)91477-6

“…Glucocorticoid replacement has been used in the management of patients with CAH for more than 40 years (Bartter et al, 1950) and this is the standard treatment for this disorder. Glucocorticoid therapy both replaces the deficient cortisol and reduces the ACTH overproduction and overstimulation of the adrenal cortex, thereby decreasing adrenal androgen secretion (Klingensmith et al, 1977;Smith et al, 1980;Antony, 1984;Winterer et al, 1985). Excessive steroid therapy in other clinical situations leads to bone loss and osteoporosis (Eastell, 1995;Sambrook et al, 1990;Adler & Rosen, 1994), but it is uncertain whether steroid replacement therapy affects bone turnover and bone mineral density (BMD) in patients with CAH.…”

mentioning

confidence: 99%

Bone turnover and bone mineral density in patients with congenital adrenal hyperplasia

Guo¹,

Weetman

²

,

Eastell³

1996

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

The 21-hydroxylase-deficient adrenal hyperplasias: More than ACTH oversecretion

Azziz¹,

Slayden²

1996

Journal of the Society for Gynecologic Investigation

View full text Add to dashboard Cite

Twenty-one hydroxylase (21-OH)-deficient classic adrenal hyperplasia (CAH) and nonclassic adrenal hyperplasia (NCAH) are two of the most common genetic disorders known to man, yet the mechanism(s) resulting in steroid excess remains unclear. Overactivation of the hypothalamic-pituitary-adrenal (HPA) axis and increased ACTH secretion appear to be important mechanisms resulting in steroid excess in untreated patients, at least in the classic forms of the disorder. Nonetheless, most NCAH patients do not demonstrate overactivity of the HPA axis. A few of these patients may demonstrate a mild degree of ACTH hyper-responsiveness to corticotropin-releasing hormone stimulation, and up to 40% have radiologic evidence of adrenocortical hyperplasia and/or isolated adenomas, suggesting that some degree of chronic ACTH excess is present. Another mechanism resulting in adrenocortical excess in adrenal hyperplasia, and primarily in NCAH, follows the alteration in enzyme kinetics resulting from the mutation of 21-OH. The mutated enzyme product is less efficient than the wild type, resulting in an increased precursor to product ratio, independent of ACTH levels. Hence, progesterone (P4) and 17-hydroxyprogesterone (17-HP) levels in these patients may remain above normal even in the presence of excess glucocorticoid administration. Overactivity of the renin-angiotensin system may also be important in stimulating adrenocortical steroidogenesis in patients with salt-wasting and in some with simple virilizing CAH. Alterations in ovarian and gonadotropic function, with the appearance of a polycystic ovary-like picture, also contribute to the androgen excess of these patients. Functional ovarian abnormalities in patients with CAH or NCAH may relate to a number of causes, including prenatal masculinization of the hypothalamic-pituitary-ovarian (HPO) axis by adrenal androgens, continued disruption of the HPO axis by persistently elevated P4 or androgen levels, and/or a direct glucocorticoid effect. Finally, these data suggest that the measurement of P4 or 17-HP may not be the most accurate marker of therapeutic efficacy, and suppression of both the ovaries and adrenals may be necessary for optimum steroidogenic control.

show abstract

The 21-Hydroxylase-Deficient Adrenal Hyperplasias: More Than ACTH Oversecretion

Azziz¹,

Slayden

²

1996

Journal of the Society for Gynecologic Investigation

View full text Add to dashboard Cite

Twenty-one hydroxylase (21-OH)-deficient classic adrenal hyperplasia (CAH) and nonclassic adrenal hyperplasia (NCAH) are two of the most common genetic disorders known to man, yet the mechanism(s) resulting in steroid excess remains unclear. Overactivation of the hypothalamic-pituitary-adrenal (HPA) axis and increased ACTH secretion appear to be important mechanisms resulting in steroid excess in untreated patients, at least in the classic forms of the disorder. Nonetheless, most NCAH patients do not demonstrate overactivity of the HPA axis. A few of these patients may demonstrate a mild degree of ACTH hyper-responsiveness to corticotropin-releasing hormone stimulation, and up to 40% have radiologic evidence of adrenocortical hyperplasia and/or isolated adenomas, suggesting that some degree of chronic ACTH excess is present. Another mechanism resulting in adrenocortical excess in adrenal hyperplasia, and primarily in NCAH, follows the alteration in enzyme kinetics resulting from the mutation of 21-OH. The mutated enzyme product is less efficient than the wild type, resulting in an increased precursor to product ratio, independent of ACTH levels. Hence, progesterone (P4) and 17-hydroxyprogesterone (17-HP) levels in these patients may remain above normal even in the presence of excess glucocorticoid administration. Overactivity of the renin-angiotensin system may also be important in stimulating adrenocortical steroidogenesis in patients with salt-wasting and in some with simple virilizing CAH. Alterations in ovarian and gonadotropic function, with the appearance of a polycystic ovary-like picture, also contribute to the androgen excess of these patients. Functional ovarian abnormalities in patients with CAH or NCAH may relate to a number of causes, including prenatal masculinization of the hypothalamic-pituitary-ovarian (HPO) axis by adrenal androgens, continued disruption of the HPO axis by persistently elevated P4 or androgen levels, and/or a direct glucocorticoid effect. Finally, these data suggest that the measurement of P4 or 17-HP may not be the most accurate marker of therapeutic efficacy, and suppression of both the ovaries and adrenals may be necessary for optimum steroidogenic control.

show abstract

Management of Congenital Adrenal Hyperplasia

Cited by 3 publications

References 7 publications

Bone turnover and bone mineral density in patients with congenital adrenal hyperplasia

Bone turnover and bone mineral density in patients with congenital adrenal hyperplasia

The 21-hydroxylase-deficient adrenal hyperplasias: More than ACTH oversecretion

The 21-Hydroxylase-Deficient Adrenal Hyperplasias: More Than ACTH Oversecretion

Contact Info

Product

Resources

About